Find Clinical Trial

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationAcute Myeloid Leukemia
SponsorInstitut de Recherches Internationales Servier
Active substance/
Medical device

AG-120, AG-221

Active Substance CodeAG-120, AG-221
Protocol CodeAG120-221-C-001
EudraCT Code2015-004290-33
NCT CodeNCT02632708


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility